Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 12/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 12/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.58 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.58 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.58 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluconazole SCHEMBL29360276 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL5597261 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL3151 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27971366 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL20305060 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL28141272 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27534402 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27971503 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL2244102 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27514614 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109845727-A | Menses save liquid and menses derived mesenchymal stem cell cryopreservation methods | 西安医斯美生物科技有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-108623585-A | Beta-tetrahydro carboline class antifungal drug and its preparation method and application | 中国人民解放军第二军医大学 | 2018-10-09 | — | — | CN | disclosed |
| EP-3322814-A1 | METHOD FOR DETERMINING THE DEGREE OF SENSITIVITY OF A STRAIN OF FUNGUS TO AN ANTIFUNGAL AGENT | Université Grenoble Alpes (FR) | 2018-05-23 | — | — | EP | disclosed |
| CN-107854423-A | A kind of ophthalmic preparation of fluconazole | 广州市桐晖药业有限公司 | 2018-03-30 | — | — | CN | disclosed |
| US-9789108-B2 | Methods of colchicine administration | HIKMA PHARMACEUTICALS LLC (JO) | 2017-10-17 | — | — | US | disclosed |
| US-9675613-B2 | Methods of colchicine administration | HIKMA PHARMACEUTICALS LLC (JO) | 2017-06-13 | — | — | US | disclosed |
| US-9555029-B2 | Methods of colchicine administration | HIKMA PHARMACEUTICALS LLC (JO) | 2017-01-31 | — | — | US | disclosed |
| US-9399036-B2 | Methods of colchicine administration | HIKMA PHARMACEUTICALS LLC (JO) | 2016-07-26 | — | — | US | disclosed |
| US-20150094318-A1 | METHODS OF COLCHICINE ADMINISTRATION | HIKMA PHARMACEUTICALS LLC (JO) | 2015-04-02 | — | — | US | disclosed |
| US-20150094317-A1 | METHODS OF COLCHICINE ADMINISTRATION | HIKMA PHARMACEUTICALS LLC (JO) | 2015-04-02 | — | — | US | disclosed |
| US-20020193384-A1 | Use of azoles for the preventing skin cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | US | disclosed |
| WO-2002005850-A2 | ENHANCEMENT OF THE ACTION OF ANTI-INFECTIVE AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | disclosed |
| EP-1032263-A1 | SURFACTANT-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS FOR USING SAME | Woodward Laboratories Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| US-6087400-A | MIXTURE CONTAINING BENZALKONIUM CHLORIDE AND WATER | WOODWARD LABORATORIES, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| US-6013677-A | APPLYING TO THE NAIL A NON-AQUEOUS ANTIMICROBIAL NAIL COATING CONTAINING A FILM FORMING POLYMER, AN ORGANIC SOLVENT, A ANTIMICROBIAL AGENT COMPRISING SOLUBILZED BENZALKONIUM CHLORIDE AND CAPABLE OF LEACHING FROM NAIL COATING | WOODWARD LABORATORIES, INC. (US) | 2000-01-11 | — | — | US | disclosed |
| US-5994383-A | MIXTURE CONTAINING BENZALKONIUM CHLORIDE AND WATER | WOODWARD LABORATORIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999036033-A1 | ANTIMICROBIAL NAIL COATING COMPOSITION | WOODWARD LABORATORIES, INC. (US) | 1999-07-22 | — | — | WO | disclosed |
| US-5908855-A | ADMINISTERING FLUCONAZOLE WITH A POTENTIATOR (ESPECIALLY PROCODAZOLE). TREATMENT OF INFLUENZA. | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-01 | — | — | US | disclosed |
| WO-1999025190-A1 | SURFACTANT-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS FOR USING SAME | WOODWARD LABORATORIES, INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1996030011-A1 | TOPICAL ANTIMYCOTIC COMPOSITIONS | BIOPLEX, L.C. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094318-A1 | METHODS OF COLCHICINE ADMINISTRATION | ABCB1, CYP3A4, CYP3A43 | CYP3A4 2/4885CYP2C9 16/4885CYP2C19 44/4885 |
| US-20150094317-A1 | METHODS OF COLCHICINE ADMINISTRATION | ABCB1, CYP3A4, CYP3A43 | CYP3A4 2/4885CYP2C9 16/4885CYP2C19 44/4885 |
| US-20020193384-A1 | Use of azoles for the preventing skin cancer | CDC73, AKR7A2, CYP51A1 | CYP3A4 105/4885CYP2C9 157/4885CYP2C19 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.